From Cell to Society by Brand, A.M.
  
 
From Cell to Society
Citation for published version (APA):
Brand, A. M. (2009). From Cell to Society. Maastricht: Maastricht University.
https://doi.org/10.26481/spe.20090904ab
Document status and date:
Published: 04/09/2009
DOI:
10.26481/spe.20090904ab
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 
 
 
 
Department of Social Medicine 
 
 
 
 
Prof. Dr. Angela Brand MD PhD MPH 
 
Head of the Department of Social Medicine 
Director of the European Centre for Public Health Genomics (ECPHG) 
 
 
 
Inaugural Lecture: “From Cell to Society” (04.09.2009) 
 
 
The Department of Social Medicine is undergoing substantial changes to meet the 
requirements of Public Health, health policy making and Public Health Medicine in the 
future. The ongoing changes in life sciences trigger an integration of all health 
determinants including genetic factors, or to be more precise, the genome and its 
interactions with environmental factors. The inaugural lecture outlines how the 
department will use this change and how it will convert the change into a positive source 
for research and education. Public Health Genomics is the internationally acknowledged 
umbrella for this enterprise. Besides Muin Khoury from CDC in Atlanta (USA) and Ron 
Zimmern from the Public Health Genomics Foundation in Cambridge (UK), Angela 
Brand had been one of the three pioneers in this field in the world. The concept of Public 
Health Genomics ensures the effective and responsible translation of innovations “from 
cell to society”. The change we see also implies that Social Medicine and Public Health 
adjust its methodologies and research approaches, a change which needs to be 
reflected in the future concept and staff composition of the department of Social 
Medicine. 
 
 
Vision of the Department of Social Medicine  
 
To improve health and prevent diseases by focussing on the highly innovative and 
cross-cutting approach “Public Health Genomics (PHG)” and by bridging Medicine and 
Public Health (Public Health Medicine) 
 
 
Mission of the Department of Social Medicine 
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To systematically translate genome-based knowledge and technologies into health 
research (assessment), health policies (policy development) and healthcare (assurance) 
on the regional, national, European and international level (Public Health Trias) 
 
 
 
 
       Public Health Trias [CDC, 2001] 
 
 
 
Goals of the Department of Social Medicine 
 
 bridging Medicine, Health and Life Sciences within UM (Public Health Medicine)  
 being complementary to the other departments and schools of the FHML within UM 
 being of added value to the other departments and schools of the FHML within UM 
 integrating PHG systematically into education and research of the FHML within UM 
 contributing to the societal impact of the FHML within UM 
 contributing strongly to regional, national, European and international visibility 
through the activities of the European Centre of Public Health Genomics (ECPHG)  
 promoting the P4 principle (Predictive, Preventive, Personalized, Participatory 
Healthcare) through the activities of the ECPHG 
 strengthening strategic partnerships with governmental bodies and industry 
 valorization through spin-offs related to PHG  
 
There are 4 major strategies to reach these goals: 
 
1. Link with PHGEN (Public Health Genomics European Network) and GRaPH-Int 
(Genome-based Research and Population Health International Network) = potential to 
become the leader in PHG not only on the European but also on the global level 
 
2. Link with the UM strategy = potential to become the hub for other departments and 
schools by serving as a Genomics Resource Centre for knowledge brokering inside 
MUMC+  
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3. Link with the EU strategy on health in all policies and other European policy 
frameworks such as the Lisbon Strategy. = potential to become the leader in European 
policy advice on Public Health Genomics   
 
4. Link with the UM holding = potential for facilitating the valorization process for 
innovations from inside and outside the university in the field of PHG, in particular in 
fields such as pharmacogenomics and nutrigenomics 
 
 
Social Medicine with the innovative profile Public Health Genomics (PHG) 
 
Traditionally, Social Medicine has always been the bridging medical discipline between 
medicine and public health. Since 1997 the European Union of the Medical Specialists 
(UEMS) is strengthening this medical speciality of Public Health in the EU medical 
specialist system by promoting the harmonization and quality of specialist medical 
training and practice in Public Health Medicine in the EU countries. Thus, in the 
Netherlands the Dutch Association of Medical Specialists (de Orde van Medisch 
Specialisten) already in 2001 described in its blueprint for medical education the 
knowledge transfer of the whole healthcare chain of primary, secondary and tertiary  
prevention as a key task of Public Health Medicine (Sociale Geneeskunde).  
 
Social Medicine as a multidisciplinary medical speciality has been very successful in the 
past by looking at interactions between the different health determinants such as clinical, 
socioeconomic, demographic, lifestyle, behavioural and environmental determinants of 
health during the whole life course (e.g., prenatal care, child and youth health, 
occupational health, health of the elderly). Social Medicine in recent years has been 
challenged by demographic change, e.g. the aging of the population.  
 
Furthermore, current clinical as well as public health interventions will fail to be effective 
and efficient, if novel knowledge such as deriving from systems biology, integrative 
genomics including epigenomics and genome-environmental interactions is not timely 
and responsibly translated into the healthcare systems. This is true not only for almost 
all public health interventions such as those regarding obesity, newborn screening, 
infectious diseases and vaccination or health promotion, but also for almost all medical 
interventions such as regarding common complex diseases like osteoporosis, 
cardiovascular diseases, cerebrovascular diseases, cancer and diabetes, which account 
for 86% of all deaths and 77% of burden of disease in Europe (Global Burden of 
Disease, 2005).    
 
Using Public Health Genomics as the new profile of Social Medicine will allow Maastricht 
University to have a unique, pioneering as well as highly innovative position in the field 
of Social Medicine in the Netherlands, in Europe as well as internationally. The matrix 
structure of the UM, the Problem-Based Learning (PBL) approach, medicine, health and 
life sciences being already “under one roof” as well as the future life and science 
campus (“campus hills”) with translational research perspectives for Maastricht UMC+ 
provide excellent opportunities to further support the European Centre for Public Health 
Genomics as the centre of excellence in this field in Europe.. 
 
 
Definition of  Public Health Genomics (PHG) 
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In 2005 the US Institute of Medicine (IOM) defined Public Health Genomics (PHG) as 
“an emerging field that assesses the impact of genes and their interaction with behavior, 
diet and the environment on the population’s health”. In the same year the international 
expert group on PHG supported by the Rockefeller Foundation defined PHG as “the 
responsible and effective translation of genome-based knowledge and  technologies into 
public policy and health services for the benefit of population health” (Bellagio statement, 
2005). Angela Brand was member of this international expert group.  
  
The task of public health genomics (PHG) has become a challenge for all healthcare 
systems having major implications for future research and policy strategies. The various 
stakeholders in public health play a key role in translating the implications of genomics 
such as deriving from systems biology, integrative genomics including epigenomics and 
genome-environmental interactions. Recent advances in systems biology indicate that 
specific cellular functions are infrequently carried out by single genes, but rather by 
groups of cellular components. This network-based research (“diseasomes”) is already 
starting to change nosology as well as to challenge population-based genetic screening 
or epidemiological methods like Health Technology Assessment (HTA). This knowledge 
will not only enable clinical interventions but also health promotion messages and 
disease prevention programmes to be targeted at susceptible individuals as well as 
subgroups of the population based on their genomic profile (personalized healthcare). 
So far there has been no systematic integration of genome-based knowledge and 
technologies into public health research, policy and practice. Thus, the public health 
agenda demands a vision that reaches beyond the research horizon to arrive at 
application and public health impact of these innovations.  
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Bellagio model of Public Health Genomics (2005) 
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The role of the European Centre for Public Health Genomics (ECPHG) 
 
The European Centre for Public Health Genomics (ECPHG) (www.ecphg.eu) is the 
European centre of excellence and “think tank” in the field of Public Health Genomics 
(PHG) operating on national, European and international level.  
 
 
 
 
European Centre for Public Health Genomics (ECPHG)
 
European Centre for Public Health Genomics (ECPHG)
 
 
 
         ECPHG (2009) 
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The ECPHG  
 coordinates the Public Health Genomics European Network (PHGEN 
www.phgen.eu) involving competent authorities from all European Member States, 
EFTA-EEA and Applicant Countries  
 has a collaboration agreement with the Institute for Prospective Technology Studies 
(IPTS) in Spain, which is one of the seven Joint Research Centers (EC-JRC) of the 
European Commission 
 is running the international journal “Public Health Genomics” with Karger publishers 
(www.karger.com/phg) 
 is leading the section on PHG within the European Public Health Association 
(EUPHA) 
 will soon be the administrative hub of the international network GRaPHint (Genome-
based Research and Population Health)  
 will become WHO Collaborating Centre in PHG (in negation phase) 
 is member of the international consortium on the harmonization of biobanking p3g 
(Public Population Projects in Genomics) 
 has established 16 national centres on PHG such as the GENAR institute in Turkey 
 is partner in various European and international projects like MUTANOM; 
EuroGentest, APOGEE/GeneTest Canada, EUREGIO, NuGO, EUnetHTA 
(European Network on Health Technology Assessment), DataProBio, BBMRI, 
EpiGenChlamydia Consortium  
 collaborates with European and international institutions such as the Max Planck 
Institute (MPI) on Molecular Genetics in Berlin/Germany, the Personal Genome 
Project at Harvard Medical School, the Public Health Agency Canada, the National 
Office of PHG at the CDC Atlanta, the European Centres for Disease Prevention and 
Control (ECDC), the European Observatory on Health Systems and Policies of WHO 
in Brussels, INSERM France 
 collaborates with industry (e.g., Roche Personalized Healthcare, Baxter, Bayer 
HealthCare) 
 has been involved in producing policy statements for institutions such as the Council 
of Europe, the OECD, the European Science Foundation (ESF), the ECDC, the 
National Competent Authorities (NCAs) of the EU, the EU on the Health Strategy, the 
EMEA on Medical Devices 
 promotes spin offs such as ALACRIS Pharmaceuticals or GENAR Gentest 
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European Centre for Public Health Genomics (ECPHG)
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     PHGEN Network of Networks and Institutions (2009) 
 
 
The coordination of the Public Health Genomics European Network (PHGEN) is one of 
the current key activities of the ECPHG. PHGEN is funded by the General Directorate for 
Health and Consumer Protection (DG SANCO) under the Health Programme of the EU.  
PHGEN II produces the 1st edition of "European Best Practice Guidelines for Quality 
Assurance, Provision and Use of Genome-based Information and Technologies", which 
assist all Member States, Applicant Countries and EFTA-EEA Countries and will strongly 
contribute to the reduction of the burden of disease in Europe. It involves key experts 
such as Public Health experts, EU lawyers, Geneticists, Ethicists, Systems Biologists, 
HTA experts, patient groups and competent authorities. Expertise from networks like 
EuroGentest, EUnetHTA, NuGO is provided to assess existing guidelines, identify gaps 
and set up a coherent, evidence-based framework for quality assurance, provision and 
use of genome-based information and technologies. PHGEN II is the follow-up of 
PHGEN I (DG SANCO 2006-2008). Whereas PHGEN I was a “mapping exercise”, 
PHGEN II systematically builds on the work of PHGEN I. It uses the concept of 
“genome-based information and technologies” (Bellagio-Model) which PHGEN I 
established as a scientific benchmark in Europe. While protecting human rights, equity in 
healthcare and solidarity amongst citizens, it meets the Lisbon Agenda objectives and 
values of the Health Strategy. 
 
 
 
 7
European Centre for Public Health Genomics (ECPHG)
PHGEN National Task Forces
June, 19th 2006 – NTF Turkey
July, 10th 2006 – NTF Italy 
November, 3rd 2006 – NTF Portugal 
November, 24th 2006 – NTF Germany
November, 29th 2006 – NTF Belgium
January, 12th 2007 – NTF Spain 
January, 24th 2007 – NTF Netherlands
September, 25th 2007 – NTF Czech Republic
October, 19th 2007 – NTF Bulgaria
November, 20th 2007 – NTF Norway
January, 30th 2008 – NTF Poland
April, 23rd 2008 – NTF Hungary
August 28th 2009 – NTF Switzerland   
In preparation: Slovenia, Iceland, Malta, Sweden, F rance …
 
 
      PHGEN National Task Forces (2009)  
 
 
„In the long run PHGEN will serve the European Commission as an ‚early detection unit‘ 
(European observatory on PHG) for horizon scanning, fact finding, and monitoring of the 
integration of genome-based knowledge and technologies into public health.“  
 
The European Centre for Public Health Genomics (ECPHG) has already a high 
European and international visibility and reputation as the centre of excellence in this 
field in Europe. Internal as well as external support ensures not only to be able to keep 
that leading position but also to further develop that field.  
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